TABLE 1.
Characteristics of included studies
| Study author (country) | Design | Median age (male%) colchicine/ Median age (male%) control | Patient setting | Intervention | Follow‐up duration | Primary outcomes |
Mechanical ventilation n/N (%) |
Mortality n/N (%) |
|---|---|---|---|---|---|---|---|---|
|
Deftereos et al 20205 (Greece) |
RCT |
63 (56.4%)/ 65 (60%) |
Inpatient | Colchicine 1.5 mg × 1 dose >0.5 mg after 60 min >maintenance of 0.5 mg BID up to 3 wk | Hospital discharge or up to 21 d |
1. Time to deterioration. 2. Maximum high‐sensitivity cardiac troponin level 3. Time for C‐reactive protein to reach more than 3 times the upper reference limit. |
Colchicine 1/55 (1.8%) Control 5/50 (10%) |
Colchicine 1/55 (1.8%) Control 4/50 (8%) |
|
Scarsi et al 20206 (Italy) |
Prospective cohort study |
69.3 (63%)/ 70.5 (64%) |
Inpatient | Colchicine 1mg OD, reduced to 0.5 mg/d if severe diarrhoea (duration NS) |
Recruitment March 5‐April 5, 2020 and patients followed till April 16 The study reported 21 d of survival. |
Survival rate | NS |
Colchicine 20/122 (16%) Control 52/140 (37.1%) |
|
Sandhu et al 202010 (USA) |
Case‐control study |
70 (64.2%)/ 65 (55.6%) |
Inpatient | Colchicine 0.6 mg BID × 3 d >0.6 mg OD up to 12 d | Follow‐up period NS |
1. Hospitalization days 2. Mortality 3. Mechanical ventilation 4. Discharge rate |
Colchicine 28/53 (52.8%) Control 106/144 (73.6%) |
Colchicine 26/53 (49%) Control 105/144 (72.9%) |
|
Brunetti et al 20202 (USA) |
Prospective cohort study | 61.2 (68.3%)/ 63 (70.7%) | Inpatient (severe COVID‐19) |
Colchicine 1.2 mg × 1 dose >Maintenance 0.6 mg BID (duration NS) |
Up to 28 d | In‐hospital mortality within 28 d | NS |
Colchicine 3/33 (9.1%) Control: 11/33 (33.3%) |
|
Lopes et al 202017 (Brazil) |
RCT | 48 (52.9%)/ 53.5 (27.8%) |
Inpatient (moderate to severe COVID‐19) |
Colchicine 0.5 mg TID × 5 d >0.5 BID ×5 d | ‐Recruitment April 11‐July 6, 2020 (follow‐up period NS) |
1. Time to need for supplemental oxygen; 2. Time to hospitalization. 3. Need for admission and length of stay in ICU 4. Death rate |
NS |
Colchicine: 0/36 (0%) Control: 2/36 (6%) |
|
Tardif et al 20208 (Canada) |
RCT |
54.4(44.6%) 54.9(47.5%) |
Outpatient (mild to moderate COVID‐19) |
0.5 mg BID × 3 d >OD × 27 d | Up to 30 d | Composite of death or hospitalization due to COVID‐19 infection |
Colchicine: 11/2235 (0.5%) Control 21/2253 (0.9%) |
Colchicine: 5/2235 (0.2%) Control: 9/2253 (0.4%) |
|
Manenti et al 202111 (Italy) |
Retrospective cohort | 60.5 (72.9%)/ 62.5 (69%) | Inpatient and outpatient | 1 mg OD till clinical improvement (up to 21 d) | Up to 21 d |
1. Differences in mortality 2. Clinical improvement 3. Inflammatory markers |
NS |
Colchicine 5/66 (7.5%) Control: 19/66 (28.5%) |
|
García‐Posada et al12 (Columbia) |
Retrospective cohort | 60 (61%) (overall, NS for each group separately) |
Inpatient (moderate to severe COVID‐19) |
Dose and duration NS | Follow‐up period NS | Differences in mortality between treatment groups | NS |
Colchicine 56/113 (49.5%) Control: 29/44 (65.9%) |
|
COLORIT 20219 (Russia) |
Quasi‐randomized trial | 61.9(66.7%)/ 59.9(72.7%) | Inpatient (moderate to severe COVID‐19) | 1 mg OD × 1‐3 d >0.5 mg OD (up to 14 d) | Up to discharge or 12 d | Changes in the SHOCS‐COVID score. | NS |
Colchicine 0 (0%) Control: 2 (9.09%) |
Abbreviations: >, followed by; BID, twice daily; COVID‐19, coronavirus disease 2019; NS, Nonspecified; OD, once daily; RCT, randomized clinical trialSHOCS‐COVID, Symptomatic Hospital and Outpatient Clinical Scale for COVID‐19.